Colorectal cancer metastatic
Not recruitingA Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer
A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabTrifluridine+1
Germany- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:AbbVie Deutschland GmbH & Co. KG











